Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>BioNTech SE’s second quarter of 2026 results reflect a company in transition, moving from its origins as a pioneering mRNA vaccine developer toward a diversified multiproduct biopharmaceutical organization, with a strong focus on oncology.</li>
<li>Leadership changes were announced with Guido Oelkers set to assume the CEO role by early 2027, bringing experience in strategic scaling and global commercialization, signaling the company’s intent to accelerate expansion and operational efficiency.</li>
<li>Operationally, BioNTech reported revenues of €106 million for Q2 2026, a decline from €261 million the prior year, largely due to reduced demand for its COVID-19 vaccine, particularly in the U.S., and reduced milestone payments.</li>
</ul>


BioNTech SE’s second quarter of 2026 results reflect a company in transition, moving from its origins as a pioneering mRNA vaccine developer toward a diversified multiproduct biopharmaceutical organization, with a strong focus on oncology.
Leadership changes were announced with Guido Oelkers set to assume the CEO role by early 2027, bringing experience in strategic scaling and global commercialization, signaling the company’s intent to accelerate expansion and operational efficiency.
Operationally, BioNTech reported revenues of €106 million for Q2 2026, a decline from €261 million the prior year, largely due to reduced demand for its COVID-19 vaccine, particularly in the U.S., and reduced milestone payments.


BioNTech Is Moving Beyond COVID — Three Oncology Programs Could Define What Comes Next!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>
<a href="https://smartkarma.com/entities/biontech-se">BioNTech </a>is strategically pivoting from its singular success with the Comirnaty COVID-19 vaccine to establishing itself as a multi-product oncology company, leveraging its pioneering mRNA technology and substantial cash reserves.</li>
  <li>The company's extensive late-stage pipeline is the core of its value proposition, with multiple pivotal data readouts expected in 2026 across various modalities, including mRNA cancer immunotherapies, ADCs, and next-generation immunomodulators.</li>
  <li>Near-term financials are under pressure due to collapsing COVID-19 vaccine demand, resulting in negative profitability and cash flow as the company heavily invests in R&amp;D to bring its oncology candidates to market, with the first launches anticipated from 2026 onwards.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
BioNTech is strategically pivoting from its singular success with the Comirnaty COVID-19 vaccine to establishing itself as a multi-product oncology company, leveraging its pioneering mRNA technology and substantial cash reserves.
  The company's extensive late-stage pipeline is the core of its value proposition, with multiple pivotal data readouts expected in 2026 across various modalities, including mRNA cancer immunotherapies, ADCs, and next-generation immunomodulators.
  Near-term financials are under pressure due to collapsing COVID-19 vaccine demand, resulting in negative profitability and cash flow as the company heavily invests in R&amp;D to bring its oncology candidates to market, with the first launches anticipated from 2026 onwards.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.</li>
<li>In terms of quantity and quality of innovations <a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US)</a>  and <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna (MRNA US)</a>  are best positioned. Among private companies Senda Biosciences screened well. </li>
<li>Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.</li>
</ul>


In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.
In terms of quantity and quality of innovations Alnylam Pharmaceuticals (ALNY US)  and Moderna (MRNA US)  are best positioned. Among private companies Senda Biosciences screened well. 
Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.


Who Are Leading the Charge in the RNAissance of Medicine

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/3sbio-inc" target="_blank" data-smartkarma-citation="entities:459:1" rel="noopener">3SBio Inc (1530 HK)</a> signed an outlicensing deal worth more than $6B with Pfizer for its PD-1/VEGF bispecific antibody, SSGJ-707. Since signing the deal, 3SBio shares rallied more than 55%.</li>
<li>Considering deals signed with Chinese companies for bispecific antibody drug candidates in recent times, 3SBio seems to have secured best valuation for its asset.</li>
<li>Initiation of global trial of SSGJ-707 and data readout from its ongoing China trials for additional indications, continued strong financial performance, and new approvals are upcoming catalysts.</li>
</ul>



3SBio Inc (1530 HK) signed an outlicensing deal worth more than $6B with Pfizer for its PD-1/VEGF bispecific antibody, SSGJ-707. Since signing the deal, 3SBio shares rallied more than 55%.
Considering deals signed with Chinese companies for bispecific antibody drug candidates in recent times, 3SBio seems to have secured best valuation for its asset.
Initiation of global trial of SSGJ-707 and data readout from its ongoing China trials for additional indications, continued strong financial performance, and new approvals are upcoming catalysts.


3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?

<ul>
<li>BioNTech SE’s full-year and fourth-quarter 2025 update highlights a transitional period marked by stable revenue and a strategic pivot toward oncology-driven growth.</li>
<li>Total revenue reached approximately EUR 2.9 billion, slightly higher year over year.</li>
<li>Performance was supported by continued leadership in COVID-19 vaccines—distributed across more than 180 countries with over 50% market share in key regions—along with EUR 613 million in collaboration payments from Bristol Myers Squibb (BMS).</li>
</ul>


BioNTech SE’s full-year and fourth-quarter 2025 update highlights a transitional period marked by stable revenue and a strategic pivot toward oncology-driven growth.
Total revenue reached approximately EUR 2.9 billion, slightly higher year over year.
Performance was supported by continued leadership in COVID-19 vaccines—distributed across more than 180 countries with over 50% market share in key regions—along with EUR 613 million in collaboration payments from Bristol Myers Squibb (BMS).


BioNTech’s Bold Oncology Push — Can Its Late-Stage Pipeline Unlock the Next Blockbuster Era?

Germany

BioNTech SE provides biotechnological solutions. The Company develops various types of treatments for cancer patients' tumors. BioNTech serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BioNTech (BNTX US)

BioNTech Is Moving Beyond COVID — Three Oncology Programs Could Define What Comes Next!

BioNTech SE’s second quarter of 2026 results reflect a company in transition, moving from its origins as a pioneering mRNA vaccine developer toward...

Baptista Research

Primer: BioNTech (BNTX US) - Aug 2026

BioNTech is strategically pivoting from its singular success with the Comirnaty COVID-19 vaccine to establishing itself as a multi-product...

αSK Primers

Who Are Leading the Charge in the RNAissance of Medicine

RNA therapeutics: We analyze the field and spotlight top players driving this precision medicine, for tackling rare diseases with innovative solutions

Pyari Menon

3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?

3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...

Tina Banerjee

BioNTech’s Bold Oncology Push — Can Its Late-Stage Pipeline Unlock the Next Blockbuster Era?

BioNTech SE’s full-year and fourth-quarter 2025 update highlights a transitional period marked by stable revenue and a strategic pivot toward...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

BioNTech Is Moving Beyond COVID — Three Oncology Programs Could Define What Comes Next!

BioNTech SE’s second quarter of 2026 results reflect a company in transition, moving from its origins as a pioneering mRNA vaccine developer toward...

Baptista Research

Primer: BioNTech (BNTX US) - Aug 2026

BioNTech is strategically pivoting from its singular success with the Comirnaty COVID-19 vaccine to establishing itself as a multi-product...

αSK Primers

Who Are Leading the Charge in the RNAissance of Medicine

RNA therapeutics: We analyze the field and spotlight top players driving this precision medicine, for tackling rare diseases with innovative solutions

Pyari Menon

3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?

​3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...

Tina Banerjee

BioNTech’s Bold Oncology Push — Can Its Late-Stage Pipeline Unlock the Next Blockbuster Era?

BioNTech SE’s full-year and fourth-quarter 2025 update highlights a transitional period marked by stable revenue and a strategic pivot toward...

Baptista Research

3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...